Study Title
APAL2020D: A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML
Protocol ID
APAL2020D
Disease (Sub Disease)
Acute myeloid leukemia
Diagnosis Stage
Relapsed/refractory
Location
QLD, VIC, WA, NZ
Sponsor
LLS PedAL Initiative, LLC
Collaborators
Princess Maxima Center for Pediatric Oncology (European Sponsor)
AbbVie
Roche-Genentech
EuPAL
AbbVie
Roche-Genentech
EuPAL
Links
Trial Status
Open
Sites
Perth Children's Hospital
Queensland Children's Hospital
Starship Hospital
Royal Children's Hospital
Queensland Children's Hospital
Starship Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
29 Days to 21 Years
International registry ID's
NCT05183035
| Study Title | APAL2020D: A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML |
|---|---|
| Protocol ID | APAL2020D |
| Disease (Sub Disease) | Acute myeloid leukemia |
| Diagnosis Stage | Relapsed/refractory |
| Location | QLD / VIC / WA / NZ |
| Sponsor | LLS PedAL Initiative, LLC |
| Collaborators | Princess Maxima Center for Pediatric Oncology (European Sponsor)/ AbbVie/ Roche-Genentech/ EuPAL |
| Links | https://clinicaltrials.gov/ct2/show/NCT05183035 |
| Trial Status | Open |
| Trial Open Date | 01/10/2022 |
| Sites | Perth Children's Hospital/ Queensland Children's Hospital / Starship Hospital / Royal Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | 29 Days to 21 Years |
| International registry ID's | NCT05183035 |